KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity: 2017-2025

Historic Common Equity for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$4.1 million.

  • Aquestive Therapeutics' Common Equity rose 90.95% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 90.95%. This contributed to the annual value of -$60.2 million for FY2024, which is 43.51% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Common Equity stood at -$4.1 million, which was up 94.34% from -$72.6 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Common Equity ranged from a high of -$4.1 million in Q3 2025 and a low of -$118.6 million during Q4 2022.
  • Over the past 3 years, Aquestive Therapeutics' median Common Equity value was -$60.9 million (recorded in 2025), while the average stood at -$67.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 151.40% in 2021, then skyrocketed by 90.95% in 2025.
  • Aquestive Therapeutics' Common Equity (Quarterly) stood at -$82.1 million in 2021, then crashed by 44.34% to -$118.6 million in 2022, then climbed by 10.18% to -$106.5 million in 2023, then surged by 43.51% to -$60.2 million in 2024, then spiked by 90.95% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$72.6 million for Q2 2025, and -$60.9 million during Q1 2025.